Stocks Health care JUNS
NASDAQ · Health careJupiter Neurosciences, Inc. (JUNS)
It posted a net loss of $9.2M. At June 30, 2026 it held $1.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Jupiter Neurosciences, Inc. does
Jupiter Neurosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JUNS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $21.8K | -$8.6M | -$0.25 | n/a |
| 2024 | $0 | -$2.4M | -$0.08 | n/a |
| 2024 | n/a | -$4.8M | -$0.18 | n/a |
Full financial statements: income, balance sheet and cash flow
Where JUNS ranks in Health care
Latest SEC filings
What Jupiter Neurosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 22, 2026Passive stake (5% or more) SCHEDULE 13G
- September 3, 2026
- August 28, 2026Passive stake changed SCHEDULE 13G/A
- August 28, 2026Passive stake (5% or more) SCHEDULE 13G
- August 28, 2026
- August 27, 2026
- August 24, 2026Other event 8-K
- August 24, 2026
- August 24, 2026
Insider trades
What the people running Jupiter Neurosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 2, 2026 | Hayward Marshall A.Chief Scientific Officer, Director | Exercised options | 225,000 | - |
Who owns JUNS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| PharmAla Biotech Holdings Inc.13G, passive | 17.3% | September 22, 2026 |
Largest institutional holders
Insiders
5 insiders reported holding 3,887,494 shares in total, about $10.4M at the last price.
| Holder | Shares |
|---|---|
| Hayward Marshall A.Chief Scientific Officer, Director | 2,995,077 |
| Rosen Alexander Gustaf ErikChief Administrative Officer | 617,411 |
| Weis HolgerDirector | 96,581 |
| Hemmerly Nicholas H.Director | 95,550 |
| Kampf Julie B.Director | 82,875 |
Questions about JUNS
What does Jupiter Neurosciences, Inc. do?
Jupiter Neurosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JUNS.
Is Jupiter Neurosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $9.2M.
When did Jupiter Neurosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shelf registration to sell securities from September 25, 2026.
Similar companies
Compare JUNS with
Follow JUNS
Get an email when Jupiter Neurosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow JUNS: get an email when it filesWhere the numbers come from
Financial figures are the values Jupiter Neurosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.